BCL2L1 and hepatocellular carcinoma: In this sense, BCL-xL-selective inhibitors, such as A-1331852, will avoid dose-limiting neutropenia although its platelet effect may complicate its use as a single agent, particularly in some cirrhotic patients with HCC.